A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation

被引：4

作者：

Su, Xiaorui ^{[1
]}

Li, Yuxuan ^{[2
]}

Ren, Yupeng ^{[2
]}

Cao, Mingbo ^{[2
]}

Yang, Gaoyuan ^{[2
]}

Luo, Jing ^{[3
]}

Hu, Ziyi ^{[1
]}

Deng, Haixia ^{[2
]}

Deng, Meihai ^{[2
]}

Liu, Bo ^{[1
]}

Yao, Zhicheng ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hepatobiliary Pancreat Splen Surg, Guangzhou 510630, Peoples R China

[2] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hepatobiliary Surg, Guangzhou 510630, Peoples R China

[3] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, Guangzhou 510630, Peoples R China

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2024年 / 176卷

关键词：

Liver cancer; Drug resistance; Epigenetic; UNRESECTABLE HEPATOCELLULAR-CARCINOMA; RETINOIC ACID; HISTONE H3; MULTIDRUG-RESISTANCE; 1ST-LINE TREATMENT; OVARIAN-CANCER; STEM-CELLS; OPEN-LABEL; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION;

D O I：

10.1016/j.biopha.2024.116902

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Drug resistance in hepatocellular carcinoma has posed significant obstacles to effective treatment. Recent evidence indicates that, in addition to traditional gene mutations, epigenetic recoding plays a crucial role in HCC drug resistance. Unlike irreversible gene mutations, epigenetic changes are reversible, offering a promising avenue for preventing and overcoming drug resistance in liver cancer. This review focuses on various epigenetic modifications relevant to drug resistance in HCC and their underlying mechanisms. Additionally, we introduce current clinical epigenetic drugs and clinical trials of these drugs as regulators of drug resistance in other solid tumors. Although there is no clinical study to prevent the occurrence of drug resistance in liver cancer, the development of liquid biopsy and other technologies has provided a bridge to achieve this goal.

引用

页数：13

共 50 条

[1] Targeting Notch signaling pathway as an effective strategy in overcoming drug resistance in ovarian cancer
Akbarzadeh, Maryam
Akbarzadeh, Shabnam
Majidinia, Maryam
PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (11)
[2] New Strategy for Overcoming Resistance to Chemotherapy of Ovarian Cancer
Kigawa, Junzo
YONAGO ACTA MEDICA, 2013, 56 (02) : 43 - 50
[3] A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin
Saw, Phei Er
Park, Jinho
Jon, Sangyong
Farokhzad, Omid C.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2017, 13 (02) : 713 - 722
[4] Nanomedicines for Overcoming Cancer Drug Resistance
Hu, Tingting
Gong, Hanlin
Xu, Jiayue
Huang, Yuan
Wu, Fengbo
He, Zhiyao
PHARMACEUTICS, 2022, 14 (08)
[5] Overcoming drug resistance in pancreatic cancer
Long, Jiang
Zhang, Yuqing
Yu, Xianjun
Yang, Jingxuan
LeBrun, Drake G.
Chen, Changyi
Yao, Qizhi
Li, Min
EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (07) : 817 - 828
[6] Epigenetic regulation of targeted ferroptosis: A new strategy for drug development
Ouyang, Shengli
Zeng, Zeyao
He, Jieyi
Luo, Lianxiang
JOURNAL OF PHARMACEUTICAL ANALYSIS, 2024, 14 (10)
[7] The new concepts on overcoming drug resistance in lung cancer
Zhang, Weisan
Lei, Ping
Dong, Xifeng
Xu, Cuiping
DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 735 - 743
[8] Ways for Overcoming Drug Resistance in Cancer: Designing New Drugs: Invited Commentary
Aksoy, Yasemin
TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, 2010, 30 (06): : 2011 - 2016
[9] Epigenetic Regulation of Claudin-1 in the Development of Ovarian Cancer Recurrence and Drug Resistance
Visco, Zachary R.
Sfakianos, Gregory
Grenier, Carole
Boudreau, Marie-Helene
Simpson, Sabrina
Rodriguez, Isabel
Whitaker, Regina
Yao, Derek Y.
Berchuck, Andrew
Murphy, Susan K.
Huang, Zhiqing
FRONTIERS IN ONCOLOGY, 2021, 11
[10] Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance?
Szumilak, Marta
Wiktorowska-Owczarek, Anna
Stanczak, Andrzej
MOLECULES, 2021, 26 (09):

← 1 2 3 4 5 →